

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Antibiotics Chemotherapy



APRIL 2003
VOLUME 7
NUMBER 1

Visit the ISC website at:
www.ischemo.org

4	Meeting report
6	ECC-5 programme
8	Vaccine against epidemic meningitis in Africa
9	Topics in food safety - Raw milk fudge
10	Prudent use of antibiotic therapy in nosocomial urinary tract infections
11	ISC-DNS CAP 2003
12	Oral AIDS vaccine
13	Metallo-carbapenemases and extended-spectrum β -lactamases
14	Society News
15	WHO News Obituary
16	Diary dates

Bacterial active efflux pumps: a lifestyle

For surviving in hostile conditions, or for conquering new territories, bacteria need to have some control over their immediate environment. In particular, most possess the capacity to reject foreign molecules that would have produced serious damage by intracellular penetration (antibiotics and biocides, for example). In addition, pumps can extrude poorly diffusible or toxic endogenous molecules from the cytosol. These pumps, or active efflux systems, are substrate transporters requiring energy generated by adenosine triphosphate (ATP) or proton motive pumps for their function. Several dozen bacterial pumps have been described so far, belonging to five superfamilies as described in Figure 1 and Table 1. The major facilitation and ATP-binding cassette superfamilies cross the prokaryote/eukaryote borders.

Efflux pumps

The pump is a protein inserted into the cytoplasmic membrane, often composed of 12 transmembrane domains (Figure 2, page 3). It has been proposed that the tertiary structure includes two similar channels, each made from six transmembrane domains, allowing bi-directional crossing: one proton getting in, one substrate molecule getting out (anti-port). In Gram-negative bacteria, which possess two membranes, the pump molecule has to contain a porin structure in the outer membrane and a fusion periplasmic protein joining the two membranes (Figure 3, page 3).




Figure 1: Classes of active efflux systems in bacteria: major facilitation superfamily (MFS) or small multidrug resistance (SMR)[1]; multiple antimicrobial extrusion (MATE)[2]; ATP binding cassette (ABC)[3]; resistance nodulation division (RND)[4].

Table 1: Examples of active efflux systems, classified into superfamilies

Efflux superfamily	Typical example (bacterial species)	Antibiotic substrate profile
Major facilitation superfamily (MFS)	NorA (<i>Staphylococcus aureus</i>)	Quinolones, chloramphenicol
ATP binding cassette (ABC)	MrsA (<i>S. aureus</i>)	Macrolides
Small multidrug resistance (SMR)	EmrE (<i>Escherichia coli</i>)	Tetracycline
Multiple antimicrobial extrusion (MATE)	YdhE (<i>E. coli</i>)	Quinolones, trimethoprim
Resistance nodulation division (RND)	Multidrug efflux transporter B (MexB)	Most β -lactams, quinolones, tetracycline, macrolides, chloramphenicol, rifampin, trimethoprim, sulfonamides, fusidic acid

ATP, Adenosine triphosphate.

The function of efflux systems

Active efflux systems can serve several functions. In *Pseudomonas aeruginosa*, efflux systems have been associated with virulence, since efflux deficient mutants exhibit diminished capacity for invasion in experimental

models.¹ Multidrug efflux transporter F (MexF) in *P. aeruginosa* contributes to quorum-sensing regulation affecting secretion of virulence factors.² Export of toxins or locally produced antibiotics are also possible functions.^{3,4} A very

continued on page 3

continued from page 1


important function is intrinsic and acquired antibiotic resistance. Most antibiotic classes can be affected by efflux, as shown in Table 1. In Gram-negative bacteria, activation or repression of efflux systems, such as those belonging to the resistance nodulation division (RND) family, can produce troublesome multi-resistant phenotypes. Of particular concern is the fact that one substrate can select resistance to structurally unrelated antibiotics. Quinolones for example can select for carbapenem resistance.⁵ Since some efflux include biocides in their substrate spectrum,⁶ biocides can induce antibiotic resistance, at least *in vitro*, but the molecular basis of such large substrate profiles is not fully understood. It has been proposed that the pump may recognize amphiphilic molecules, the hydrophobic moiety being inserted into the cytoplasmic membrane. The recent recognition, however, that aminoglycosides could be efflux substrates does not fit with this view.⁷ Within a given antibiotic class, all molecules are not similarly affected by efflux resistance. For example, PmrA in *Streptococcus pneumoniae* extrudes ciprofloxacin about eight times more efficiently than moxifloxacin or gatifloxacin. In *P. aeruginosa*, meropenem but not imipenem is a substrate of the MexB pump. In streptococci, macrolide resistance by efflux is limited to 14- and 15-membered compounds. Efflux mechanisms in general, confer a low to moderate level of resistance (1- to 64-fold increase in minimal inhibitory concentration),⁸ which is not necessarily clinically significant, particularly in Gram-positive organisms. Efflux resistance is also often associated with other resistance mechanisms, such as topoisomerase mutations in the case of quinolones, or outer membrane permeability alterations with the carbapenems. Efflux activation may allow delayed entry of antibiotic molecules, providing

more time for selection of a second resistance mechanism. Many efflux genes are located on the bacterial chromosome, but others, such as Tet transporters, are found on plasmids.

Future developments

Active ongoing research is trying to develop anti-efflux strategies that will allow circumvention of efflux resistance and restoration of wild-type susceptibility, a strategy already used successfully with β -lactamase inhibitors. A number of compounds, for example

reserpine, omeprazole or phenothiazines, exert their inhibitory properties against both prokaryotic and eukaryotic efflux systems, limiting their clinical potential as pump inhibitors. More specific compounds are, however, under investigation,⁹ including tetracycline derivatives directed against Tet transporters, flavonolignans (natural alkaloids) active against NorA in *Staphylococcus aureus*, and an exciting series of small peptide inhibitors of RND transporters in *P. aeruginosa*.¹⁰ §



Jean-Claude Pechère
Universities of Geneva and Marrakech
President of the ISC




Figure 2: Two-dimensional model of a resistance nodulation division pump, with 12 transmembrane domains. This is thought to form two channels, one for the entry of a proton providing the energy, and the other for extrusion of the substrate molecule.¹¹





Figure 3: Model of the resistance nodulation division pump. Substrate amphiphilic molecules (hydrophobic moiety in green), coming either from the outside or from the cytosol, are extracted from the cytoplasmic membrane by the pump.¹²

References

1. Hirakata Y, Srikumar R, Poole K, Gotoh N, Suematsu T, Kohno S *et al*. Multidrug efflux systems play an important role in the invasiveness of *Pseudomonas aeruginosa*. *J Exp Med* 2002; 196: 109-118.
2. Kohler T, van Delden C, Curty LK, Hamzehpour MM, Pechère JC. Overexpression of the MexEF-OprN multidrug efflux system affects cell-to-cell signaling in *J Bacteriol* 2001; 183: 5213-5222.
3. Shariff A, Fanutti C, Shi J, Calladine C, Luisi B. The role of the TolC family in protein transport and multidrug efflux. From stereochemical certainty to mechanistic hypothesis. *Eur J Biochem* 2001; 268: 5011-5026.
4. Cundliffe E. Self-protection mechanisms in antibiotic producers. *Ciba Found Symp* 1992; 171: 199-208.
5. Kohler T, Michea-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of *Pseudomonas aeruginosa*. *Mol Microbiol* 1997; 23: 345-354.
6. Poole K. Mechanisms of bacterial biocide and antibiotic resistance. *J Appl Microbiol* 2002; 92 (Suppl): 55S-64S.
7. Aires JR, Kohler T, Nikaido H, Plesiat P. Involvement of an active efflux system in the natural resistance of *Pseudomonas aeruginosa* to aminoglycosides. *Antimicrob Agents Chemother* 1999; 43: 2624-2628.
8. Lomovskaya O, Lee A, Hoshino K, Ishida H, Mistry A, Warren MS *et al*. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1999; 43: 1340-1346.
9. Lomovskaya O, Watkins WJ. Efflux pumps: their role in antibacterial drug discovery. *Curr Med Chem* 2001; 8: 1699-1711.
10. Renau TE, Leger R, Flamme EM, Sangalang J, She MW, Yen R *et al*. Inhibitors of efflux pumps in *Pseudomonas aeruginosa* potentiate the activity of the fluoroquinolone antibacterial levofloxacin. *J Med Chem* 1999; 42: 4928-4931.
11. Paulsen IT, Brown MH, Skurray RA. Proton-dependent multidrug efflux systems. *Microbiol Rev* 1996; 60: 575-608.
12. Nikaido H. Multidrug efflux pumps of Gram-negative bacteria. *J Bacteriol* 1996; 178: 5353-5359.


Table 1
Some Preferred Compounds of the Invention Displaying Inhibition of the Efflux Pump of *Staphylococcus aureus* 1199 B
(Nor A⁺)



Entry	X	R ₁	R ₂	R ₅	R ₇	FIC INDEX #
1.	C-F	C ₂ H ₅	COOH	H	4-acetoxypiperidin-1-yl	0.314
2.	C-F	C ₂ H ₅	COOH	H	4-{2-(2-oxazolidin-1-yl)ethyl}piperazin-1-yl	0.188
3.	C-H	c-C ₃ H ₅	COOH	H	3,5-dimethyl-4-ethylpiperazin-1-yl	0.314
4.	C-H	c-C ₃ H ₅	COOH	H	4-acetoxypiperidin-1-yl	0.282
5.	C-F	c-C ₃ H ₅	COOH	NH ₂	(1,2,2,6,6-pentamethylpiperidin-4-yl)-N-methylamino	0.314
6.	N	c-C ₃ H ₅	COOH	H	Pyrrolidin-3-ylamino	0.188
7.	C-F	CH(CH ₃)-CH ₂ CH ₂ SC ₆ H ₅	COOC ₂ H ₅	H	4-hydroxypiperidin-1-yl	0.100
8.	C-H	C ₆ H ₄ CF ₃ (2)	COOH	H	3,3,4-trimethylpiperazin-1-yl	0.282
9.	C-F	C ₆ H ₄ CF ₃ (2)	COOH	NH ₂	morpholin-1-yl	0.314
10.	C-F	C ₆ H ₄ CF ₃ (2)	COOH	NH ₂	3,5-dimethylpiperazin-1-yl	0.314
11.	C-H	C ₆ H ₄ F(4)	COOH	H	4-(ethylamino)piperidin-1-yl	0.189
12.	C-F	C ₆ H ₃ F ₂ (2,4)	COOH	NH ₂	3-hydroxy-5-methylpyrrolidin-1-yl	0.314
13.	C-F	C ₆ H ₃ F ₂ (2,4)	COOH	NH ₂	3,3-dimethylpiperazin-1-yl	0.375
14.	N	C ₆ H ₃ F ₂ (2,4)	COOH	H	4-aminopiperidin-1-yl	0.314
15.	N	C ₆ H ₃ F ₂ (2,4)	COOC ₂ H ₅	H	{(1α,5α,6α)-3-N-benzyl-3-azabicyclo[3.1.0]hex-6-yl} amino	0.185

16.	C-CH ₂ CH ₂ C**H(CH ₃)	COOCH ₂ COOC ₂ H ₅	H	4-hydroxy-piperidin-1-yl	0.400
17.	C-CH ₂ CH ₂ C**H(CH ₃)	COO-piperidin-N-CH ₃	H	4-hydroxy-piperidin-1-yl	0.370
18.	C-CH ₂ CH ₂ C**H(CH ₃)	COO-CH ₂ CH ₂ -morpholine	H	4-hydroxy-piperidin-1-yl	0.180

Examples of Bis compounds of the invention Displaying Inhibition of the Efflux Pump of *Staphylococcus aureus* 1199 B (Nor A) (continuation of the table 1)




Entry	R ₁	R ₅	X	n	Z	Y	R ₁ '	R ₅ '	X'	FIC INDEX#
19	c-C ₃ H ₅	H	CH	1	CH	NH	C ₆ H ₃ F ₂ (2,4)	H	N	0.253
20	c-C ₃ H ₅	CH ₃	CH	1	CH	NH	C ₆ H ₃ F ₂ (2,4)	H	N	0.320

- # MIC against *S. aureus* 1199B for all compounds is less than or equal to 6.25 µg/ml, except for entry Nos. 3 and 6, MIC is 3.12 µg/ml; for entry Nos. 5, 9, 18 MIC is 1.56 µg/ml. and for entry No 17 MIC is 0.8 µg/ml.

- ** R-isomer; *S-isomer; absence of an asterisk indicates that the substance is a racemic compound.

Table 2

Some Preferred Compounds of the Invention Displaying Inhibition of the Efflux Pumps of *Pseudomonas aeruginosa* 23587



Entry. X	R ₁	R ₂	R ₅	R ₇	Difference in Zone diameter Z ¹ (mm) #
1. C-H	c-C ₃ H ₅	COOH	CH ₃	4-methoxypiperidin-1-yl	13
2. C-OCH ₃	c-C ₃ H ₅	COOH	H	4-amino-3,3-dimethyl-piperidin-1-yl	12
3. C-OCH ₃	c-C ₃ H ₅	COOH	H	4-hydroxy-3,3-dimethyl-piperidin-1-yl	8
4. C-H	c-C ₃ H ₅	COOH	H	3,5-dimethyl-4-ethylpiperazin-1-yl	8
5. C-F	C ₂ H ₅	COOH	H	(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hex-3-yl	7
6. N	C ₆ H ₃ (2,4-F ₂)	COOH	H	piperidin-4-ylamino	6
7. N	c-C ₃ H ₅	COOH	H	4-amino-3-ethyl-piperidin-1-yl	6
8. C-CH ₂ CH ₂ CH(CH ₃)		COOH	H	4-(D-phenylalanyloxy)piperidin-1-yl hydrochloride	12
9. C-CH ₂ CH ₂ C*(H)(CH ₃)		COOH	H	4-(D-leucyloxy)piperidin-1-yl hydrochloride	12
10. C-CH ₂ CH ₂ C*(H)(CH ₃)		COOH	H	4-(L-alanyloxy)piperidin-1-yl hydrochloride	9
11. C-CH ₂ CH ₂ C*(H)(CH ₃)		COPhe-Lys-OMe	H	F	8
12. C-CH ₂ CH ₂ CH(CH ₃)		COOH	H	trans-4-hydroxy-3-methyl-piperidin-1-yl	6
13. C-OCH ₂ CH(CH ₃)		COOH	H	4-hydroxy-3-ethyl-piperidin-1-yl	5

¹Z = the difference of the diameter of the zone of inhibition in the levofloxacin containing plate minus the diameter of the zone of inhibition in the water containing control plate.


- # In the assay plates used, an agar well has a diameter of 7 mm; the minimum zone of inhibition observable is 8 mm in diameter. A zone less than 8 mm is considered as "nil".

The diameters of the zones of inhibition of the test substance listed in the water-containing plate was nil : 3, 8-9 mm : 9, 11mm : 1.

- ** R-isomer; * S-isomer; absence of an asterisk indicates that the substance is a racemic compound.

Table 3

Some Preferred Compounds of the Invention Displaying Inhibition of the Efflux Pumps of *Escherichia coli* 2051



Entry.	X	R ₁	R ₂	R ₅	R ₇	Difference in Zone diameter Z ¹ (mm) #
1.	CH	c-C ₃ H ₅	COOH	CH ₃	Br	9
2.	C-OCH ₃	c-C ₃ H ₅	COOH	H	4-amino-3-methyl-piperidin-1-yl	10
3.	C-CH ₂ CH ₂ C*H(CH ₃)	c-C ₃ H ₅	COOH	H	4-hydroxypiperidin-1-yl (0.2 H ₂ O)	9
4.	C-CH ₂ CH ₂ C*H(CH ₃)	c-C ₃ H ₅	COOH	H	4-hydroxypiperidin-1-yl. [(CH ₃) ₃ N(OH)(CH ₂) ₂ OH] salt	9
5.	C-CH ₂ CH ₂ C*H(CH ₃)	c-C ₃ H ₅	COOH	H	4-hydroxypiperidin-1-yl. 1-Hydroxyethylpyrrolidine salt	11
6.	C-CH ₂ CH ₂ C*H(CH ₃)	c-C ₃ H ₅	COOH	H	4-hydroxypiperidin-1-yl . Diethanolamine salt	11
7.	C-CH ₂ CH ₂ C*H(CH ₃)	c-C ₃ H ₅	COOH	H	4-(D-leucyloxy)piperidin-1-yl hydrochloride	18
8.	C-CH ₂ CH ₂ C*H(CH ₃)	c-C ₃ H ₅	COOCH ₂ CH ₂ -morpholine	H	4-Hydroxypiperidin-1-yl	8
9.	C-CH ₂ CH ₂ C**H(CH ₃)	c-C ₃ H ₅	CO-phe-lysOMe	H	F	11
10.	C-CH ₂ CH ₂ C*H(CH ₃)	c-C ₃ H ₅	COOH	H	trans-3-methyl-4-hydroxypiperidin-1-yl	8

¹Z = the difference of the diameter of the zone of inhibition in the levofloxacin containing plate minus the diameter of the zone of inhibition in the water containing control plate.


- # In the assay plates used, an agar well has a diameter of 7 mm; the minimum zone of inhibition observable is 8 mm in diameter. A zone less than 8 mm is considered as "nil".

The diameters of the zones of inhibition of all the test substances listed in the water-containing plate was nil, except for entry 4 which was 9 mm.

- ** R-isomer; * S-isomer; absence of an asterisk indicates that the substance is a racemic compound.

Table 4

Some Preferred Compounds of the Invention Displaying Inhibition of the *mef* Efflux Pump of *Streptococcus pneumoniae* 3514



Entry.	X	R ₁	R ₂	R ₅	R ₇	Difference in Zone diameter Z ¹ (mm)
1.	C-OCH ₃	c-C ₃ H ₅	COOH	H	4-amino-3-methyl-piperidin-1-yl	26
2.	C-OCH ₃	c-C ₃ H ₅	COOCH(CH ₃) ₂	H	4-amino-3,3-dimethyl-piperidin-1-yl	11
3.	C-OCH ₃	c-C ₃ H ₅	COO(CH ₂) ₃ CH ₃	H	4-amino-3,3-dimethyl-piperidin-1-yl	11
4.	C-OCH ₃	c-C ₃ H ₅	COOCH ₂ C ₆ H ₅	H	4-(t-butoxycarbonylamino)-3,3-dimethyl-piperidin-1-yl	13
5.	C-F	c-C ₃ H ₅	COOH	NH ₂	4-amino-3-methyl-piperidin-1-yl	20
6.	N	c-C ₃ H ₅	COOH	H	(1 α ,5 α ,6 α)-3-N-benzylazabicyclo[3.1.0]hex-6-yl-amino	17
7.	N	C ₆ H ₅ (2,4-F ₂)	COOH	H	(1 α ,5 α ,6 α)-3-N-benzylazabicyclo[3.1.0]hex-6-yl-amino	15
8.	-C-OCH ₂ CH ₂ C*H(CH ₃)		COOH	H	4-aminopiperidin-1-yl	13

¹Z = the difference of the diameter of the zone of inhibition in the levofloxacin containing plate minus the diameter of the zone of inhibition in the water containing control plate.

** R-isomer; * S-isomer; absence of an asterisk indicates that the substance is a racemic compound.

Differences in An Efflux Pump Bearing Strain (*S. aureus* 1199B) to Efflux Different Fluoroquinolone Antibiotics

Bacterial strains : *S. aureus* 1199 (NorA⁻) and *S. aureus* 1199B (NorA⁺) were kindly provided by Prof. G.W.Kaatz.

Antibiotics and reserpine solution preparation : The stock solution of fluoroquinolone antibiotics and reserpine were prepared by dissolving test compounds in DMSO.

MIC Determination. Minimum Inhibitory Concentrations (MICs) were determined by NCCLS recommended agar dilution method¹ employing Mueller Hinton agar, Difco, Overnight grown culture of test strains *S. aureus* 1199 (Nor A⁻) and *S. aureus* 1199B (Nor A⁺) in Tryptic Soya Broth (TSB) were adjusted to deliver 10⁴ cfu/spot using Denley's multipoint inoculator (Applied Quality Services, UK). Antibacterial agents were evaluated using 2 fold dilutions in the concentration range of 0.0125 – 50 mcg/ml in the absence and presence of (20mcg/ml) efflux pump inhibitor, reserpine. The plates were incubated at 35°C for 18 h. MICs were read as the lowest concentration of drug that completely inhibited bacterial growth.

¹ National Committee for Clinical Laboratory Standards. (2000). M7-A5. 5th edn.
National Committee for Clinical Laboratory Standards, Wayne.PA

Table 1 MICs of fluoroquinolone antibiotics in a Nor A efflux pump bearing strain, *S. aureus* 1199B, in the absence of and presence of the efflux pump inhibitor, reserpine.

Antibiotics	MIC (mcg/ml)		Lowering of MIC (X times) In the presence of Reserpine
	<i>S. aureus</i> 1199B (Nor A ⁺)	<i>S. aureus</i> 1199B (Nor A ⁺) + Reserpine (20 mcg/ml)	
Ciprofloxacin	6.25	0.8	8
Sitafloxacin	0.4	0.05	8
Norfloxacin	12.5	3.12	4
Clinafloxacin	0.2	0.05	4
Gemifloxacin	0.2	0.05	4
Levofloxacin	0.8	0.4	2
Gatifloxacin	0.4	0.2	2
Moxifloxacin	0.2	0.2	0

- The more the lowering of MIC , the higher the efflux of antibiotic in *S. aureus* 1199B

Table 2. Evidence of presence of resistance mechanism other than efflux in *S. aureus* 1199B (Nor A⁺)

Antibiotics	MIC (mcg/ml)			X times Higher MICs Of (N) compared to (L)
	<i>S. aureus</i> 1199 Nor A ⁻ (L)	<i>S. aureus</i> 1199B (Nor A ⁺) (M)	<i>S. aureus</i> 1199B (Nor A ⁺) + Reserpine (20 mcg/ml) (N)	
Norfloxacin	3.12	12.5	3.12	0
Gemifloxacin	0.05	0.2	0.05	0
Ciprofloxacin	0.4	6.25	0.8	2
Sitafloxacin	0.025	0.4	0.05	2
Levofloxacin	0.2	0.8	0.4	2
Gatifloxacin	0.1	0.4	0.2	2
Clinafloxacin	0.0125	0.2	0.05	4
Moxifloxacin	0.05	0.2	0.2	4

- MICs of antibiotics in presence of reserpine for *S. aureus* 1199B (NorA⁺) not matching with those of sensitive *S. aureus* 1199 (NorA⁻) is indicative of other underlying resistance mechanisms of action in *S. aureus* 1199 (NorA⁺) Strain.

Clastogenicity and Human Topoisomerase II Inhibition Profiles of Non-Fluorinated Quinolones (NFQs)

V. A. MURPHY, B. LEDOUSSAL, P. J. RENICK, T. L. TWINEM, and T. W. MORRIS*

Procter & Gamble Pharmaceuticals, Mason, OH, USA

41st Interscience Conference on
Antimicrobial Agents and
Chemotherapy September 22-25, 2001
Chicago, Illinois

*Contact at: morris.tw@pg.com

Table 1: In Vitro Activity Comparison of Fluorinated (FQ) and Non-Fluorinated Quinolones (NFQs)

NFQ/FQ Pair	Compound	R ₆	R ₇	R ₈	Microbes (LOEL (µg/mL))	Topo II Inhibition (IC ₅₀ (µg/mL))	S. aureus MIC (µg/mL)	E. coli MIC (µg/mL)	Core Structure
Pair 1	PGE-103714	H	H ₂ N-CH ₂ -CH ₂ -O	Cl	>400	600	0.06	0.03	
Pair 2	Cladofloxacin	F	3-amino-pyridine	Cl	160	400	0.016	0.008	
Pair 3	PGE-0099633	H	H ₂ N-CH ₂ -CH ₂ -O	F	>400	300	0.12	0.03	
Pair 4	PGE-141812	F	3-amino-pyridine	F	64	300	0.016	0.004	
Pair 5	PGE-0099633	H	H ₂ N-CH ₂ -CH ₂ -O	OMe	1000	>600	<0.06	<0.06	
Pair 6	PGE-9713121	F	3-amino-pyridine	OMe	64	400	0.03	0.016	
Pair 7	PGE-404276	H	H ₂ N-CH ₂ -CH ₂ -O	OMe	>2500	600	0.3	0.12	
Pair 8	Galofloxacin	F	3-methyl-pyridine	OMe	400	300	0.06	0.06	
Pair 9	PGE-9509924	H	H ₂ N-CH ₂ -CH ₂ -O	OMe	400	>600	0.016	0.03	
Pair 10	PGE-7257720	F	3-amino-pyridine	OMe	160	300	0.06	0.12	
Pair 11	PGE-9262032	H	H ₂ N-CH ₂ -CH ₂ -O	OMe	1000	>600	<0.005	0.03	
Pair 12	PGE-9213375	F	3-amino-pyridine	OMe	400	600	0.008	0.008	

Results & Conclusions

- 6 of 6 NFQs bearing various substituents at both the R₇ and R₈ positions showed reduced microsome induction relative to their FQ counterparts. 5 of these NFQs also showed reduced human topoisomerase II inhibition (Fig. 1 and Fig. 2).
- These data suggest that certain NFQs may have substantially reduced potential for microsome induction.
- While the relative antibacterial potency of these 6 NFQs (especially PGE-9262032) were highly active, with MICs against *S. aureus* and *E. coli* that were comparable to their respective counterparts.
- Although these NFQs are consistently less potent in *in vitro* corresponding FQ (Fig. 1 and Fig. 2), substituents at both the R₇ and R₈ position within the NFQ series still influenced potency according to previously established trends for FQs (Table 1).

References

- Hopfer, D. C. 1999. Mode of action of fluoroquinolones. *Drugs*, 58, Suppl. 2, 5-10.
- Sun, M. J., J. M. Dougherty, G. E. Raband, G. B. Mallouk, and M. A. Cohen. 1992. Pharmacokinetic relationships between in vivo and *in vitro* antibacterial activity. *J. Med. Chem.* 35:1741-1750.
- Lehoucq, B., J. K. Almond, S. M. Plum, C. F. Guller, J. L. G. X. Zhang, 1999. Novel non-fluorinated quinolones, mechanism of action, and design of new, potent and safe agents. Abstract F-564, 39th ICAAC, San Francisco, CA.
- Boydoukhury, S. T., J. P. Smith, K. M. Mohr, E. J. McInnes, B. Ledoussal, and C. E. Crummett. 2001. Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant *Escherichia coli* and *Stenotrophomonas maltophilia*. *J. Antimicrob. Chemother.* 48:39-46.
- Boydoukhury, S. T., C. E. Crummett, E. J. McInnes, H. D. McKee, K. M. Mohr, P. M. Kopp, and B. Ledoussal. 2001. Quinolone resistance in *Stenotrophomonas maltophilia* and *Escherichia coli*: molecular mechanisms in whole cells and clinical isolates. *Antimicrob. Agents Chemother.* 45:1115-1120.
- National Committee for Clinical Laboratory Standards. 1997. Method for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Doc. M7-A4.
- Chavakis, V., M. J. Sun, and J. C. Threlk. 1993. High capacity *in vitro* assay for measurement of ribonucleic damage. *Antim. Agents* 285:227-236.

Fig. 1. Microsome Induction





Fig. 2. Topoisomerase II Inhibition



Abstract

Background: Previously we reported a series of Non-Fluorinated Quinolones (NFQs) with potent antibacterial activity and sharply reduced genotoxicity relative to their 6-fluoroquinolone analogs (FQs). To test if additional NFQs also show reduced genotoxicity, an expanded set of 6 NFQ/FQ pairs (including cladofloxacin and galofloxacin benchmarks) were purified *in vitro* by microsome induction and human topoisomerase II inhibition assays. **Methods:** *In vitro* genotoxicity was assessed by measuring microsome induction in Chinese hamster ovary cells without metabolic activation using a concentration range of 1.6 - 2500 µg/mL. Inhibition of human topoisomerase II catalytic activity was measured using a reduction of supercoiled plasmid DNA over a concentration range of 1 - 600 µg/mL. **Results:** No microsome induction was observed for 3 of the 6 NFQs, while minimal induction was observed for the remaining 3 (LOELs of 160 to 400 µg/mL). For the 6 NFQ/FQ pairs, the LOELs for the 6 NFQs ranged from 64 - 400 µg/mL, including 160 and 400 µg/mL for cladofloxacin and galofloxacin, respectively. In human topoisomerase II assays, K2561 for these NFQs were <600, <600, 600, 600, 600, and 300 µg/mL. In contrast, K2561 for the 6 FQs were 600, 400, 300, 400, 300, and 100 µg/mL, respectively. **Conclusions:** For these NFQ/FQ pairs, the 6 NFQs clearly show reduced *in vitro* genotoxicity, while still retaining significant antibacterial potency. Although these NFQs are consistently less potent *in vitro* than corresponding FQs, inhibition at the 7 and 8 positions still influenced genotoxicity within the NFQ series according to previously established trends for FQs.

Introduction

Antibacterial quinolone drugs act by inhibiting the function of essential type II bacterial DNA topoisomerases (1). However, quinolones also have been shown to be genotoxic in mammalian cells (2). In addition, quinolones have been shown to be genotoxic in mammalian cells (3). Although the precise molecular mechanism(s) remains elusive, the genotoxic effects of quinolone antibiotics are presumed to result from overlapping inhibition of similar type II topoisomerases present in mammalian cells. In previous reports (4,5), we have 6-4 substituted quinolones (NFQs) were described which show unique, unexpected biological properties relative to their 6-4 substituted counterparts (FQs). Specifically, some of these novel NFQs display surprising antibacterial potency against problematic drug-resistant pathogens (e.g., *Stenotrophomonas maltophilia*, *Stenotrophomonas maltophilia*, and *Pseudomonas aeruginosa*) while also demonstrating significant potential for mechanism-based genotoxicity. This unique combination of antibacterial potency and reduced genotoxicity has challenged previously established SAR trends for quinolones (2). Here, we describe the *in vitro* genotoxicity and antibacterial activity of a series of 6 NFQ/FQ pairs which illustrate unique aspects of quinolone activity-genotoxicity relationships for NFQs.



Methods

Antibacterial Compounds and Assays: Test compounds were synthesized at P&G Pharmaceuticals. Growth inhibition MICs were measured against *S. aureus* M137 and *E. coli* E3142 by standard microsome dilution assays (6). **Topoisomerase II Assays:** Human topoisomerase II (p170 form) was purchased from Topogen, Inc. (Columbus, OH) and assayed for reduction activity according to the manufacturer's instructions, with supercoiled pBR322 plasmid DNA as the substrate. Reaction products were separated on 1% agarose TAE gels, stained with ethidium bromide, and visually inspected to determine IC50 values. **Microsome Induction Assays:** *In vitro* microsome induction was conducted at Corning Laboratories, Inc. (Ypsilanti, MI) using Human Ovary (CHO) cells in compliance with OECD guidelines (7). Cells were first treated with metabolic inhibitors (ethanol and sodium azide) and then incubated with test compounds for 24 hours. Cells were then fixed in methanol/acetic acid, stained with orcinole orange, and fluorescent cells were scored for microsome induction (7). **Genotoxicity Effect Levels (LOELs)** were reported as the lowest non-cytotoxic compound concentrations resulting in ≥4.0% microsome-induced cells and were significantly different (p < 0.05) relative to vehicle controls.

Camagni, J.E. Gray, A.E. III, N.K. Nili, H.D.N. Procter & Gamble Pharmaceuticals, Mason, OH.

*Comments on
1513: 6:2-9999 (T4)
1513: 6:2-9999 (F5)
1513: 6:2-9999 (F5)

Background



Conclusions

As previously discussed, the contribution of the 7 position side chain has a more dramatic effect on antibacterial activity in the NFO series than in the fluoroquinolone series.

The presence of an additional small lipophilic moiety in the vicinity of the terminal nitrogen attached to the 7 side chain improves significantly the overall amphiphilic polarity of the fluorocarbonureas. In the pyrimidine as well as acetonide series.

Using small molecule modeling and a simple algorithm, a new type quinoline architectural side chain leading to liquid broad spectrum agents has been designed.

This work indicates that further investigation in the NQF sector can lead to new types of companies. Indeed, extremely promising entrepreneurial opportunities.

of

ICAC 1929 #32827 F-544

J. Med. Chem. 1993, 36, 8471-887.

Abstract: F-2142

Citation: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, September and December 2001, page 251

Comparison of High-Field NMR, Circular Dichroism, and Gel Electrophoresis for Assessing Binding of Antibacterial Agents and Topoisomerase Inhibitors to DNA.

K.M. MAKIN, A.F. RUSSELL, T.L. TWINEM, C.E. CATRENICH, B. LEDOUSSAL, T.W. MORRIS

Procter & Gamble Pharmaceuticals, Mason, OH

Background: As part of an antibacterial drug discovery program to identify inhibitors of Type II bacterial topoisomerases (e.g. DNA gyrase), we sought practical methods for measuring binding of potential DNA topoisomerase inhibitors to double-stranded DNA. To assist rapid exclusion of topoisomerase inhibitors that act via nonselective binding to DNA substrates, we compared 3 experimental approaches for characterizing the binding of small molecule ligands to DNA. **Methods:** High-field solution NMR (based on linewidth broadening of aromatic protons from test ligands), circular dichroism (CD; based on DNA conformation shifts), and agarose gel electrophoresis (based on DNA mobility shifts) methods were compared against a common set of DNA binding ligands and DNA topoisomerase inhibitors. NMR experiments assessed binding to sonicated calf-thymus DNA, while CD and gel electrophoresis experiments assessed binding to supercoiled pBR322 bacterial plasmid DNA. **Results:** When challenged by known DNA binders (e.g. ethidium bromide, aminoacridine) and benchmark topoisomerase inhibitors (e.g. ciprofloxacin, novobiocin), the gel electrophoresis method gave inconsistent, non-quantitative gel shift profiles. The CD method was more predictive but was also labor-intensive and highly susceptible to minor method variations. The NMR method was clearly the most predictive, quantitative, and robust technique. **Conclusions:** The NMR method provides reliable and quantitative rank ordering of strong DNA binders (e.g. ethidium bromide), moderate binders (e.g. chloroquine), and weak DNA binders (e.g. ciprofloxacin). These data can be used to guide the rational design and optimization of antibacterials that selectively target Type II bacterial topoisomerases.

1: J Toxicol Environ Health. 1996 Feb 9;47(2):115-23.

Effects of new quinolone antibacterial agents on mammalian chromosomes.

Shimada H, Itoh S.

Developmental Research Laboratory, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.

The clastogenic effects of several new quinolones (ciprofloxacin, enoxacin, levofloxacin, nalidixic acid, ofloxacin, pipemidic acid, and N1-cyclopropyl quinolones for drug candidate) were studied cytogenetically using Chinese hamster lung cells (CHL) and the mouse micronucleus test. Some N1 cyclopropyl quinolones strongly induced chromosomal aberration on CHL cells, and some, but not all, were also capable of inducing micronuclei in mouse bone marrow cells. Levofloxacin showed weak clastogenicity in CHL cells but did not induce either micronuclei in mouse bone marrow or unscheduled DNA synthesis (UDS) in rat hepatocytes when administered to intact live animals. The lack of concordance between in vitro and in vivo assays could reflect the differences in the tissue levels of the drugs and the in vitro conditions.

PMID: 8598568 [PubMed - indexed for MEDLINE]

1: Toxicol Lett. 1999 Jan 11;104(1-2):43-8.

Chromosomal aberrations in human lymphocytes exposed in vitro to enrofloxacin and ciprofloxacin.

Gorla N, Garcia Ovando H, Larripa I.

Facultad de Agronomia y Veterinaria, UNRC, Rio Cuarto, Argentina.

Chromosomal aberrations were evaluated in cultures of human peripheral lymphocytes from eight healthy donors, exposed to the antimicrobial enrofloxacin (EFX) or to its major metabolite ciprofloxacin (CFX). In both treatments cultures revealed an increase in the chromosomal aberration level, detected as chromatid and chromosome breaks and gaps. Control cultures analysis revealed $3. \pm 0.6$ chromosomal aberrations per 100 cells while treated cultures exhibited 8.3 ± 0.8 and 9.6 ± 1.2 aberrations at 5 and 50 microg/ml of EFX respectively. In CFX treated cultures it was found 5.6 ± 1.3 and 7.7 ± 3.5 aberrations/100 cells at 5 and 25 microg/ml antimicrobial concentration. The results suggested a genotoxic effect of EFX and CFX in the system used ($P < 0.001$). A reduction in the mitotic index and fuzzy metaphases were observed at 50 microg/ml of CFX, indicating a cytotoxic effect produced by this antimicrobial.

PMID: 10048748 [PubMed - indexed for MEDLINE]